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a b s t r a c t
Amanita phalloides, also known as ‘death cap’, is one of the most poisonous mushrooms, being involved
in the majority of human fatal cases of mushroom poisoning worldwide. This species contains three main
groups of toxins: amatoxins, phallotoxins, and virotoxins. From these, amatoxins, especially α-amanitin,
are the main responsible for the toxic effects in humans. It is recognized that α-amanitin inhibits RNA
polymerase II, causing protein deficit and ultimately cell death, although other mechanisms are thought
to be involved. The liver is the main target organ of toxicity, but other organs are also affected, especially
the kidneys. Intoxication symptoms usually appear after a latent period and may include gastrointestinal
disorders followed by jaundice, seizures, and coma, culminating in death. Therapy consists in supportive
measures, gastric decontamination, drug therapy and, ultimately, liver transplantation if clinical condition
worsens. The discovery of an effective antidote is still a major unsolved issue. The present paper examines
the clinical toxicology of A. phalloides, providing the currently available information on the mechanisms
of toxicityinvolved and on the current knowledge on the treatment prescribed against this type of mush-
rooms. Antidotal perspectives will be raised as to set the pace to new and improved therapy against these
mushrooms.
© 2015 Elsevier Ltd. All rights reserved.
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In the past few decades, mushrooms have become popular
in the human diet as a result of their exquisite taste and tex-
ture, protein content, and an expanding body of scientific re-
search supporting their health benefits (Cheung, 2010). The in-
creased public demand for wild edible mushrooms contributes
to an increased interest in their picking and consumption (Pilz
and Molina, 2002), which enhances the risk of intoxications by
toxic mushrooms (Eren et al., 2010). Despite warnings on the
risks, collectors may confuse edible with toxic mushrooms, due
to misidentification based on morphological characteristics. Toxic
mushrooms can be grouped based on their toxic components: cy-
clopeptides, gyromitrin, muscarine coprine, isoxazoles, orellanine,
psilocybin, and gastrointestinal irritants (Karlson-Stiber and Pers-
son, 2003). From these, cyclopeptides-containing mushrooms are
the most toxic species throughout the world, being responsible for
90–95% of human fatalities (Karlson-Stiber and Persson, 2003). The
main toxic agents are amatoxins that are present in three gen-
era: Amanita (mainly Amanita phalloides, A. virosa and A. verna);
Lepiota (the most frequently reported is L. brunneoincarnata) and
Galerina (the most common being Galerina marginata) (Table 1)
(Enjalbert et al., 2002). Among these species, A. phalloides is re-
sponsible for the majority of fatal cases due to mushroom poison-
ing (Alves et al., 2001; Bonnet and Basson, 2002; Diaz, 2005b; Vet-
ter, 1998). Amatoxin poisoning usually has a bad prognosis due to
the high risk of liver failure. There are no worldwide widely ac-
cepted guidelines regarding the treatment of amatoxins-intoxicated
patients and therapy comprises supportive care and numerous
combinations of drugs, including antibiotics and antioxidant ther-Table 1
Amatoxin-containing mushroom species from the genera Amanita, Galerina and Le-
piota.
Amanita sp. Galerina sp. Lepiota sp.
A. phalloides G. badipes L. brunneoincarnata
A. bisporigera G. beinrothii L. brunneolilacea
A. decipiens G. fasciculate L. castanea
A. hygroscopica G. helvoliceps L. clypeolaria
A. ocreata G. marginata L. clypeolarioides
A. suballiacea G. sulciceps L. felina
A. tenuifolia G. unicolor L. fulvella
A. verna G. venenata L. fuscovinacea



































py. Several antidotes have been used, namely benzylpenicillin,
eftazidime, silybin, and N-acetylcysteine. However, none of them
as been clearly proven to have great clinical efficacy and, there-
ore, a high mortality rate (10–30%) is still verified (Enjalbert et al.,
002; Escudie et al., 2007; Ganzert et al., 2005). Survival depends
n the degree of hepatic destruction, the ability of the remaining
iver cells to regenerate, and the management of complications that
ay develop during the intoxication course (Koda-Kimble et al.,
012). Liver transplantation has significantly improved the survival
ate in A. phalloides poisoned patients and remains the cornerstone
f treatment in selected patients with fulminant hepatic failure
Broussard et al., 2001; Pinson et al., 1990). However, organ trans-
lant services totally depend on available organ donation, which is
ot always possible, being also a costly and risky procedure.
Accurate estimates of worldwide poison by amatoxins-
ontaining mushrooms are difficult to establish due to the
ack of case reporting in hospital emergency rooms. To the best
f our knowledge, in Portugal there is only one retrospective
nalysis that gathered the data of 93 cases of mushroom poi-
onings admitted in ten Portuguese hospitals between 1990 and
008. Of those, 63.4% were attributed to amatoxins-containing
ushrooms, 11.8% having a fatal outcome (Brandão et al., 2011).
n USA, a total of 6600 mushroom intoxications were reported
o the national poison data system of the American association
f poison control centers in 2012 (Mowry et al., 2013). Among
hese cases, 82.7% were attributed to unknown mushroom types
hile cyclopeptides-containing mushrooms represented 44 cases
4 patients died) (Mowry et al., 2013). A retrospective case study
oncerning the prevalence and the circumstances of exposure to
ushrooms reported to the Swiss toxicological information center
etween January 1995 and December 2009 described a total of
2 confirmed cases of amatoxin poisoning, 5 with a fatal outcome
Schenk-Jaeger et al., 2012). A retrospective study of all amatoxin
oisoning cases recorded over 15 years (1988–2002) in the Tox-
cological Unit of Careggi General Hospital (Florence University)
eported 111 intoxications by amatoxins-containing mushrooms
reated with benzylpenicillin (2 patients died) (Giannini et al.,
007), while available clinical French data described 45 patients
1984–1989) treated with benzylpenicillin plus silybin (8 patients
ied) (Jaeger et al., 1993). From the above information, it is clear
hat amatoxin poisoning has emerged as a serious public health
roblem worldwide. Therefore, this review aims to provide the
tate of the art concerning the mechanisms of toxicity, patterns
f clinical presentation and management of amatoxin poisoning,




Amatoxins are present in several Basidiomycota species belong-
ng to three genera, i.e. Amanita, Galerina, and Lepiota (Barceloux,
008; Block et al., 1955; Kaneko et al., 2001). Table 1 lists the
ain amatoxin-containing species (Enjalbert et al., 2002). As case



























































 R1 R2 R3 R4 R5 
Phalloidin OH H CH CH OH 
Phalloin H H CH CH OH 
Prophallin H H CH CH H 
Phallisin OH OH CH CH OH 
Phallacin H H CH(CH ) COOH OH 
Phallacidin OH H CH(CH ) COOH OH 























Fig. 1. Chemical structure of phallotoxins.
 X R1 R2 
Viroidin SO2 CH3 CH(CH3)2
Deoxoviroidin SO CH3 CH(CH3)2
Alaviroidin SO2 CH3 CH3
Viroisin SO2 CH2OH CH(CH3)2


































eports of fatalities following consumption of amatoxins-containing
ushrooms are mainly associated with A. phalloides (Barceloux,
008), this species will be the main focus of the present review.
The smooth moist cap of A. phalloides is greenish yellow, darker
n the center and faintly streaked radially. The cap is 6–12.5 cm
cross and easily peeled. The stalk is smooth, white and 6–12.5 cm
igh. There is an irregular ring near the top of the stalk and a bul-
ous cup at the base. The fruiting body emanates a sweetish and
ot unpleasant smell. Its taste is pleasant, according to the sur-
ivors after intoxication (Bonnet and Basson, 2002). A. phalloides is
istinguished from other species, like Volvariella volvacea, by their
rregular ring near the top of the stalk, the bulbous cup at the
ase and white gills under the cap that are not attached to the
tem. The morphology of the bulbous cup has been an important
eature to distinguish Amanita from other resembling genera. How-
ver, inexperienced collectors break the specimen off at the stem
estroying or neglecting some of these characteristics, which puts
he consumers at risk of intoxication (Olson et al., 1982). More-
ver, non-Amanita containing-amatoxins species exist placing more
eople at risk (Olson et al., 1982). Additionally, mushroom species
ave mutable appearances at different times of year and at dif-
erent locations, depending on weather, soil, and time of harvest,
hich makes more challenging the correct mushroom identifica-
ion for collectors.
.2. Habitat and distribution
A. phalloides is the predominant European poisonous mush-
oom, particularly in Central and Occidental Europe (Barceloux,
008). Several cases of A. phalloides poisoning have also been re-
orted in northeastern United States (Pond et al., 1986), Central
nd South America, Asia (Karlson-Stiber and Persson, 2003), Aus-
ralia, (Trim et al., 1999) and Africa (Reid and Eicker, 1991). This
pecies is an ectomycorrhizal fungus that forms symbiotic relation-
hips with a variety of tree species, such as beech, oak, chestnut,
nd pine. The best seasons of the year for A. phalloides fructifi-
ation are spring, late summer, and autumn (Bonnet and Basson,
002), and therefore the majority of the intoxication cases occur
n those seasons.
.3. Main toxins and most poisonous parts of A. phalloides
A. phalloides contains three classes of cyclic peptide toxins,
hich can be grouped into amatoxins, phallotoxins, and virotoxins.
ll groups of toxins contain a tryptophan residue substituted at po-
ition 2 of the indol ring by a sulfur atom (Vetter, 1998) (Figs. 1–3).
hey have distinct toxicological profiles: amatoxins are highly toxic
intraperitoneal lethal dose 50 (LD50) 0.4–0.8 mg/kg, in the white
ouse] causing death within 2–8 days, whereas phallotoxins and
irotoxins are less toxic (intraperitoneal LD50 1–20 mg/kg, in the
hite mouse) but act quickly, causing death within 2–5 h (Vetter,
998).
Several studies have studied the content and distribution of the
ain toxins in different carpophore tissues and in several develop-
ent stages of A. phalloides (Enjalbert et al., 1996, 1999, 1993; Gar-
ia et al., 2015c). An unequal distribution of the toxins throughout
he carpophore exists. The highest amatoxins content was found
n the ring, gills and cap, while the volva had the richest in the
mount of phallotoxins (Enjalbert et al., 1993; Garcia et al., 2015c).
he collection site and the age of the collected species affect the
uantity of toxins on the carpophore elements (Enjalbert et al.,
996, 1993; Garcia et al., 2015c). The collection site (mainly soil
haracteristics) determines toxins’ composition of each mushroom,
ostly the predominance of either acidic or neutral phallotoxins
Enjalbert et al., 1996; Garcia et al., 2015c). Regarding the matu-
ation state, the content of amatoxins is relatively high during thearly development stages (button, button with broken outer veil,
nd pileus revealed from outer veil) and decreases in the mature
completely developed fruit body with convex cap) and old (wilted
ruit body with reflexed cap) stages (Garcia et al., 2015c; Hu et al.,
012).
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 R1 R2 R3 R4 R5 
α-amanitin CH2OH OH NH2 OH OH 
β-amanitin CH2OH OH OH OH OH 
γ-amanitin CH3 OH NH2 OH OH 
ε-amanitin CH3 OH OH OH OH 
Amanin CH2OH OH OH H OH 
Amanin amide CH2OH OH NH2 H OH 
Amanullin CH3 H NH2 OH OH 
Amanullic acid CH3 H OH OH OH 






























































































Phallotoxins are bicyclic heptapeptides, first isolated from
A. phalloides (Lynen and Wieland, 1938) and formed by at least
seven different compounds: phalloidin, phalloin, prophallin, phal-
lisin, phallacin, phallacidin, and phallisacin (Fig. 1) (Vetter, 1998).
From these, phalloidin, phalloin, prophallin, and phallisin are clas-
sified as neutral phallotoxins, whereas phallacin, phallacidin, and
phallisacin are acidic phallotoxins.
The in vitro actions of phallotoxins have been thoroughly char-
acterized (Cooper, 1987; Dancker et al., 1975; Gabbiani et al., 1975;
Wieland, 1976). Phallotoxins bind to F-actin, which stabilizes the
actin filaments and prevents microfilaments depolymerization, dis-
turbing the correct function of the cytoskeleton (Wieland, 1976).
They are only toxic to mammals if parenterically administered
since phallotoxins are not absorbed through the gastrointestinal
tract (Wieland and Faulstich, 1978). The major in vivo toxic effect
produced by intraperitoneal administration of phallotoxin affects
the liver (Wieland, 1976). The LD50 values of phallotoxins for white
mouse are listed in Table 2. All phallotoxins have similar intraperi-
toneal LD50 (ranging from 1.5 to 4.5 mg/kg), except prophalloin,
which seems to be less toxic (>20 mg/kg). No significant toxico-
logical data on neutral and acid phallotoxins exist so far, thus no
final conclusions can be drawn regarding their putative toxicologi-
cal differences.
2.5. Virotoxins
Virotoxins are monocyclic peptides formed by at least five dif-
ferent compounds: alaviroidin, viroisin, deoxoviroisin, viroidin, andeoxoviroidin (Fig. 2) (Vetter, 1998). The structure and biological
ctivity of virotoxins are similar to that of phallotoxins, thus sug-
esting that virotoxins are biosynthetically derived from phallotox-
ns or share common precursor pathways (Brossi, 1991; Derelanko
nd Hollinger, 2001). As with phallotoxins, virotoxins are not con-
idered to have significant toxic effects after oral exposure. At the
olecular level, like phallotoxins, they interact with actin, stabiliz-
ng the bonds between actin monomers and preventing microfila-
ents depolymerization. However, the ultraviolet-spectra of inter-
ction between actin and virotoxins is different from that of actin-
hallotoxins, suggesting a different molecular interaction (Turcotte
t al., 1984). Virotoxins have a more flexible structure when com-
ared with phallotoxins and the presence of two additional hy-
roxyl groups may provide different reactivity (Fig. 2) (Faulstich
t al., 1980; Wong, 2013). The intraperitoneal LD50 of virotoxins
n mice ranges from 1.0 to 5.1 mg/kg (Table 2) and their main
oxicological feature is hemorrhagic hepatic necrosis caused by
n interaction of the virotoxins with outer surface of the hepato-
yte through unknown mechanisms (Loranger et al., 1985). At this
oint, the role of virotoxins in human toxicity remains unclear, al-
hough due to its poor oral absorption, little clinical importance is
iven to this class of toxins.
.6. Amatoxins
Amatoxins have been identified as bicyclic octapeptides with
olecular weight of around 900 g/mol, formed by at least
ine different compounds: α-amanitin, β-amanitin, γ -amanitin, ε-
manitin, amanin, amaninamide, amanullin, amanullinic acid, and
roamanullin (Fig. 3) (Vetter, 1998). From these, α-amanitin, γ -
manitin, amaninamide, amanullin, and proamanullin are classified
s neutral amatoxins, whereas β-amanitin, ε-amanitin, amanin,
nd amanullic acid are acidic amatoxins. The intraperitoneal LD50
f amatoxins in mice ranges from 0.3 to 20 mg/kg (Table 2). The
ain toxicological studies were focused on α-amanitin and β-
manitin toxins, thus no final conclusions can be drawn regard-
ng the potential differences between neutral and acid amatoxins.
matoxins only differ by the number of hydroxyl groups and by
n amide carboxyl exchange (Fig. 3) (Vetter, 1998). These toxins
ave great heat stability and this property combined with their
olubility in water make them exceptionally toxic as they are not
estroyed by cooking or drying (Wieland and Faulstich, 1978). In
ddition, amatoxins are resistant to enzyme and acid degrada-
ion, and therefore when ingested they will not be inactivated
n the gastrointestinal tract (Wieland and Faulstich, 1978). A fa-
al case was reported after consuming A. phalloides frozen during
–8 months, thus demonstrating that these compounds also resist
o freeze/thawing processes (Himmelmann et al., 2001). Addition-
lly, amatoxins decompose very slowly when stored in open, aque-
us solutions or following prolonged exposure to sun or neon light
Barceloux, 2008).
.6.1. Toxicokinetics of amatoxins
The toxicokinetics of α-amanitin has been studied in animals
nd through data obtained in reports of human poisoning by am-
toxins (Faulstich et al., 1985; Jaeger et al., 1993). Amatoxins are
eadily absorbed from the human gastrointestinal tract and can be
etected radioimmunologically in the urine as early as 90–120 min
fter ingestion (Homann et al., 1986). Amatoxins do not bind to al-
umin (Faulstich et al., 1985) being rapidly eliminated from the
lood and distributed to liver and kidneys within 48 h (Jaeger
t al., 1993). After intravenous administration in dogs, the plasma
alf-life of amatoxins was shown to be short, ranging from 26.7 to
9.6 min and they were not detectable in plasma after 4–6 h. The
otal body clearance was between 2.7 and 6.2 ml/min/kg (Faulstich
t al., 1985).
J. Garcia et al. / Food and Chemical Toxicology 86 (2015) 41–55 45
Table 2
LD50 values for amatoxins, phallotoxins, and virotoxins in different species and administration routes.
Toxin Micea Rata Doga Humana Administration route References
Amatoxins
α-amanitin 0.3–0.6 4.0 Intraperitoneal (Wieland and Faulstich, 1978)
0.002 0.01 Intracerebroventricular (Wieland and Faulstich, 1978)
0.1 Intravenous (Wieland and Faulstich, 1978)
0.1 Oral (Vetter, 1998)
β-amanitin 0.5 Intraperitoneal (Deshpande, 2002)
γ -amanitin 0.2–0.5 Intraperitoneal (Deshpande, 2002)
ε-amanitin 0.3–0.6 Intraperitoneal (Deshpande, 2002)
Amanin 0.5 Intraperitoneal (Deshpande, 2002)
Amanin amide 0.5 Intraperitoneal (Deshpande, 2002)
Amanullin >20 Intraperitoneal (Deshpande, 2002)
Amanullinic acid >20 Intraperitoneal (Deshpande, 2002)
Proamanullin >20 Intraperitoneal (Deshpande, 2002)
Phallotoxins
Phalloin 1.5 Intraperitoneal (Deshpande, 2002)
Phalloidin 2 Intraperitoneal (Deshpande, 2002)
Phallisin 2 Intraperitoneal (Deshpande, 2002)
Prophalloin >20 Intraperitoneal (Deshpande, 2002)
Phallacin 1.5 Intraperitoneal (Deshpande, 2002)
Phallacidin 1.5 Intraperitoneal (Deshpande, 2002)
Phallisacin 4.5 Intraperitoneal (Deshpande, 2002)
Virotoxins
Alaviroidin 3.7 Intraperitoneal (Loranger et al., 1985)
Viroisin 1.68 Intraperitoneal (Loranger et al., 1985)
Deoxoviroisin 3.35 Intraperitoneal (Loranger et al., 1985)
Viroidin 1.0 Intraperitoneal (Loranger et al., 1985)
Deoxoviroisin 5.1 Intraperitoneal (Loranger et al., 1985)


































































The liver is the primary target organ of toxicity of amatoxins,
nd hepatocellular effects represent the most lethal and the least
reatable manifestation of that toxicity (Karlson-Stiber and Persson,
003). In fact, due to the gastrointestinal absorption of amatoxins,
t is expected that the liver is the first organ to enter in contact
ith a large amount of those toxins. Amatoxins accumulate in the
iver upon uptake via OATP located in the sinusoidal membrane
f hepatocytes (Fig. 4). Letschert et al. (2006) identified OATP1B3
s the main human uptake transporter for amatoxins. Amatoxins
ere analyzed in the liver following 2 fatal intoxications and in the
iver of 2 patients who underwent liver transplantation, showing
hat high levels of amatoxins levels [α-amanitin ranged from not
etected to 19 ng/g; β-amanitin ranged from not detected to 3298
g/g (the method limit detection is 5 ng/mL)] (Jaeger et al., 1993).
Amatoxins do not undergo metabolism and they are excreted
n large quantities in the urine during the first days following in-
estion, with maximal excretion occurring in the first 72 h (Jaeger
t al., 1993). A small amount can be eliminated in bile and may be
eabsorbed via the enterohepatic circulation, which prolongs the
ody burden to these toxins (Faulstich et al., 1985). Intestinal elim-
nation also seems to occur. In a human intoxication report (Jaeger
t al., 1993) 6.3 mg of α-amanitin was eliminated in the feces over
period of 24 h; this amount is believed to be lethal in an adult.
Possibly due to the preferential elimination route through the
idney, nephrotoxicity has also been reported (Mydlik and Derz-
iova, 2006). The concentration found in the kidney has been
hown to be 6 to 90 times higher than in the liver (Jaeger et al.,
993). Moreover, our group has performed an in vivo study (Wistar
ats) with different α-amanitin doses (10 and 21.4 mg/kg, i.p.) and
acrifice times (2 and 4 h). The results showed higher levels of to-
al α-amanitin in the kidney than in the liver (Garcia et al., 2015a).
herefore, although classically amatoxins are considered hepatic
oxins, putative renal failure has to be evaluated.
.6.2. Clinical toxicology
The symptomatology of amatoxin poisoning can extend from a
imple gastroenterological disorder to death. Signs and symptomsf α-amanitin poisoning are mainly attributable to the accumula-
ion of α-amanitin in the liver and kidneys (Mydlik and Derzsiova,
006). Hepatic and renal injury does not cause symptoms until ex-
ensive damage has occurred. Thus, it is expected that the amatox-
ns clinical symptomatology becomes evident only several hours or
ven days after A. phalloides ingestion.
Three distinct phases of the A. phalloides toxic syndrome have
een established in the literature: 1) gastrointestinal phase, 2) la-
ent period and 3) the hepatorenal phase (Karlson-Stiber and Pers-
on, 2003).
The first stage of A. phalloides syndrome occurs abruptly, 6–
4 h after ingestion, and is characterized by nausea, vomiting, diar-
hea (occasionally bloody), abdominal pain, and hematuria (Becker
t al., 1976). This phase usually lasts about 12–36 h. Fever, tachy-
ardia, metabolic disorders like hypoglycemia, dehydration, and
lectrolyte imbalance may occur during this phase (Barceloux,
008). It has been suggested that gastrointestinal phase manifested
fter A. phalloides ingestion is due to the presence of phallotoxins
n these mushrooms (Santi et al., 2012). However, the mechanism
y which phallotoxins cause gastrointestinal symptoms remains to
e elucidated.
The latent period is characterized by absence of symptoms,
hilst progressive deterioration of hepatic and renal function is
ccurring (Becker et al., 1976). Hepatic lesions are accompanied by
ncreased serum concentration of aspartate aminotransferase (AST),
lanine aminotransferase (ALT), and lactate dehydrogenase (LDH)
Faulstich, 1979). The blood coagulation is also severely disturbed,
hich may give rise to internal bleeding (Amini et al., 2011).
The pathological hallmark of amatoxin poisoning is the devel-
pment of liver necrosis and this characterizes the hepatorenal
hase. The patients progressively lose kidney and liver functions
nd may develop jaundice, hypoglycemia, oliguria, delirium, and
onfusion (Becker et al., 1976). This phase culminates in rapid de-
erioration of central nervous system, severe hemorrhagic manifes-
ations, renal and hepatic failure, which corresponds to a bad prog-
osis (Bonnet and Basson, 2002). About 20–79% of the intoxicated
atients develop chronic liver disease (Serne et al., 1996).
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Fig. 4. Simplified model of α-amanitin transport and main toxic mechanism in hepatocytes. α-Amanitin accumulation occurs in the liver upon uptake via an organic anion-
transporting octapeptide (OATP1B3) located in the sinusoidal membrane of hepatocytes. Once in the hepatocyte, α-amanitin binds to RNA polymerase II causing inhibition






































2.6.3. Mechanisms of toxicity induced by amatoxins
There are significant inter and intraspecies variations, concern-
ing the concentration of amatoxins in mushrooms. Therefore, an
accurate prediction of toxicity based on the amount of mushrooms
consumed is difficult (Barceloux, 2008). The lethal dose of amatox-
ins in humans has been estimated (from accidental intoxications)
to be about 0.1 mg/kg body weight (Table 2), or even lower, and
this amount may be present in a single mushroom (Karlson-Stiber
and Persson, 2003).
Several toxicity mechanisms have been attributed to amatox-
ins. The main mechanism seems to be their known ability to non-
covalently bind and inhibit RNA polymerase II (RNAP II) activity
in the nucleus (Wieland, 1983) (Fig. 5). Many experimental studies
have been conducted to get a better understanding of the inter-
action with RNAP II (Cochet-Meilhac and Chambon, 1974; Nguyen
et al., 1996; Rudd and Luse, 1996). Cochet-Meilhac and Chambon
carried out a kinetic study to evaluate the interaction of amatox-
ins with RNAP II (Cochet-Meilhac and Chambon, 1974). The au-
thors used purified calf thymus RNAP II and observed that the
equilibrium association constant is high, ranging 108-1010 (Cochet-
Meilhac and Chambon, 1974). Bushnell et al. obtained the first X-
ray elucidating the RNAP II/α-amanitin interactions. In this struc-
ture, the α-amanitin binding site was located in the interface of
subunits Rpb1 and Rpb2 (Bushnell et al., 2002). Moreover, the X-
ray structure characterization allowed to partially elucidate the key
molecular contacts that contribute to RNAP II inhibition. RNAP II
residues that interact with α-amanitin are located entirely in the
bridge helix (Bushnell et al., 2002). In particular, α-amanitin binds
directly to the bridge helix residue Glu822, through a hydrogen
bond, and indirectly to the bridge helix residue His816 (Fig. 5)
(Bushnell et al., 2002). However, it has been also proposed that
α-amanitin inhibits RNAP II by direct interference with the trigger
loop (structural element that makes direct substrate contacts and
promotes nucleotide addition) (Kaplan et al., 2008), therefore pre-
venting the conformational change of RNAP II and inhibiting the
ribonucleic acid (RNA) elongation process (Wang et al., 2006). In a
recent in silico study, we showed that α-amanitin interferes with
the bridge helix and trigger loop (Garcia et al., 2014), which alters
the elongation process and contributes to the inhibition of mes-
senger RNA (mRNA) synthesis.The decline of mRNA levels leads to the decrease of protein
ynthesis and, ultimately, to cell death (Wieland, 1983). Moreover,
guyen et al. (1996) suggested that the binding of α-amanitin
o RNAP II results in the degradation of Rpb1 subunit. The au-
hors have found, in mice fibroblasts, that α-amanitin promotes
he degradation of the Rpb1 subunit, resulting in its irreversible
nhibition (Nguyen et al., 1996). However, the characterization of
his mechanism needs further investigation.
In vitro studies have shown that apoptosis may play an impor-
ant role in α-amanitin-induced severe liver injury as observed in
og primary hepatocytes (Magdalan et al., 2010b) and in human
epatocyte cultures (Magdalan et al., 2010a, 2011). The exposure
f hepatocytes to α-amanitin (2 μM) resulted in p53-and caspase-
-dependent apoptosis (Fig. 6) (Magdalan et al., 2011). In neona-
al human diploid fibroblasts, α-amanitin (2 μg/mL) treatment for
4 h resulted in a marked induction of p53. The concentration
equired for induction of p53 was correlated with the concentra-
ion required to inhibit mRNA synthesis, suggesting a link between
hese two effects (Ljungman et al., 1999). To further evaluate the
ole of p53 in transcription inhibition-mediated cell death, p53
nock-out HTC116 cells, and wild-type cells were treated with α-
manitin (10 μg/ml) for 24 h and the extent of apoptosis was eval-
ated. The results showed that the knock-out p53 cells were less
ensitive to death induced by α-amanitin, corroborating that p53
lays an important role in α-amanitin-induced toxicity. A stress
ignal is elicited by α-amanitin, which leads to the translocation
f cytoplasmic p53 to mitochondria and an alteration of mitochon-
rial membrane permeability through formation of p53 complexes
ith protective proteins (Bcl-xL and Bcl-2) (Fig. 6). The complexes
ormation results in the release of cytochrome c into the cytosol
nd the prosecution of the intrinsic apoptotic pathway (Fig. 6)
Arima et al., 2005). These results were further corroborated
n vivo. Knockout p53/BAK mice showed marked resistance to-
ards α-amanitin (5 μg/g)-induced liver damage, while wild-type
ice in the same conditions underwent organ destruction (Leu and
eorge, 2007). An interaction between p53 and mitochondrial BAK
eems to be important for p53’s mitochondrial role in the induc-
ion of apoptosis by α-amanitin (Leu and George, 2007).
Other mechanisms might be involved in α-amanitin-induced
oxicity. It has been suggested that TNF-α exacerbates α-amanitin-
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Fig. 5. Crystal structure of 10 subunit RNA polymerase II in complex with α-amanitin. Crystal structure elucidates some of the key atomic contacts that contribute to
RNA polymerase II inhibition. RNA polymerase II residues interacting with α-amanitin are located entirely in the bridge helix (magenta). α-Amanitin binds directly through
a hydrogen bond with bridge helix residue Glu822 and indirectly with bridge helix residue His816. The α-amanitin and residues Glu822 and His816 are in the licorice
representation.
Fig. 6. Signaling pathways involved in α-amanitin-induced toxicity. The main toxicity mechanism of α-amanitin is the inhibition of RNA polymerase II. Other mechanisms
have been suggested and include the formation of reactive oxygen species (ROS) leading to oxidative stress related damage. Generation of ROS may also be induced by
increase of superoxide dismutase (SOD) activity and inhibition of catalase activity. Amatoxins may act synergistically with tumor necrosis factor (TNF), to induce apoptosis,
though the underlying mechanisms are not yet known. Amatoxins-induced apoptosis may also be caused by the translocation of p53 to the mitochondria causing alteration
of mitochondrial membrane permeability through formation of complexes with protective proteins (Bcl-xL and Bcl-2). These changes result in the release of cytochrome c
into the cytosol and activation of the intrinsic pathway of apoptosis. Question marks indicate that the mechanisms that remain unknown.




























































induced hepatotoxicity in vivo (Fig. 6) (Leist et al., 1997). After
in vivo administration of a high dose of α-amanitin, hepatic
TNF-mRNA was increased and hepatocytes underwent apoptosis,
whereas in mice treated with anti-TNF antibodies, liver injury
caused by α-amanitin was prevented (Leist et al., 1997). In ad-
dition, transgenic mice lacking the 55 kDA TNF-α receptor seem
to be relatively resistant to α-amanitin-induced toxicity (Leist
et al., 1997). Therefore, hepatocyte apoptosis may result from a
synergistic action between α-amanitin and TNF-α (Fig. 6) (Leist
et al., 1997). However, the mechanisms of such synergistic effects
remain unclear at this point and the dependence of α-amanitin
toxicity on the presence of TNF-α was not confirmed in another
study using rat hepatocyte cultures (El-Bahay et al., 1999). Thus,
TNF-α may not be indispensable for the development of cytotoxic-
ity by α-amanitin but exacerbates it. Actually, TNF-α co-treatment
significantly increased lipid peroxidation caused by α-amanitin
and this effect was prevented by silybin, indicating the possible in-
volvement of reactive oxygen species (ROS) (El-Bahay et al., 1999).
These results suggest that TNF-α induced toxicity is linked with
ROS production (El-Bahay et al., 1999). In fact, oxidative stress has
also been postulated to be important in the development of severe
hepatotoxicity in other studies (Fig. 6) (Zheleva, 2013; Zheleva
et al., 2007). In vivo, hepatic accumulation of α-amanitin leads to
an increase of superoxide dismutase (SOD) activity and malon-
dialdehyde products, and also results in the decrease of catalase
activity (Fig. 6) (Zheleva et al., 2007). Lipid peroxidation may
contribute to massive necrosis and severe hepatotoxicity (Zheleva
et al., 2007). Zheleva (2013), using the electron paramagnetic
resonance spin trapping technique, studied the in vitro and in vivo
oxidation of α-amanitin. During in vitro oxidation, α-amanitin
by itself can form unstable phenoxyl radicals. Using the same
technique, these authors found that the production of reactive
species increased in mice kidney subjected to an intraperitoneal
administration of 1 mg/kg of α-amanitin. Thus, α-amanitin is
able to form phenoxyl free radicals that might be involved in ROS
generation (Fig. 6) (Zheleva, 2013). More investigation is needed to
completely clarify the pathophysiology of ROS in the α-amanitin-
induced toxicity, as it has been a scarcely studied subject.
2.6.4. Pathophysiology of intoxications by amatoxins
2.6.4.1. Liver. As previously mentioned, the main pathophysiologic
feature of the intoxication by amatoxins is liver failure. Histopatho-
logical findings in liver biopsy specimens have shown massive cen-
trilobular hepatic necrosis (Pond et al., 1986). Acute toxic hepatitis
may develop rapidly, then reaching the state of liver insufficiency,
and ultimately coma (Mydlik and Derzsiova, 2006). Five autop-
sies were performed on patients fatally poisoned with A. phalloides
(Fineschi et al., 1996). Those autopsies revealed intensely yellow
liver of creamy consistency and diffuse subcapsular hemorrhage.
The histological examination confirmed stasis in all organs, includ-
ing liver with diffuse hemorrhagic foci. The liver showed typical
features of massive centrilobular necrosis and vacuolar degenera-
tion of hepatocytes (Fineschi et al., 1996). Pathological examina-
tions were also performed in two explanted liver after amatoxin
poisoning. The cut surface of the explanted livers was hemorrhagic
and had a nutmeg appearance. Centrilobular massive hemorrhagic
necrosis and fatty degeneration areas were also observed (Kucuk
et al., 2005).
Liver failure can lead to disseminated intravascular coagulation
due to reduced clearance of activated clotting factors, release of
pro-coagulants from damaged hepatocytes and reduced synthesis
of coagulation inhibitors, contributing to multi-organ failure (Sanz
et al., 1988; Soysal et al., 2006). Further consumption and subse-
quent exhaustion of coagulation proteins and platelets (from on-
going activation of coagulation) may culminate in severe bleeding
(Sanz et al., 1988; Soysal et al., 2006)..6.4.2. Kidney. Nephrotoxicity after A. phalloides poisoning is also
requent. Patients can develop acute tubular necrosis with kidney
ailure (Mydlik and Derzsiova, 2006). Post-mortem examinations of
atients after amatoxin poisoning showed dark red kidneys with
xtravasation of blood, especially in the cortical region. Stasis with
iffuse hemorrhagic foci, acute tubular necrosis, and massive quan-
ities of hyaline casts in the tubules were also found in patients
hat died after A. phalloides intoxication (Fineschi et al., 1996).
anconi-type renal tubular acidosis associated with A. phalloides in-
estion has also been reported (Barceloux, 2008).
.6.4.3. Central nervous system. Neurologic manifestations, either
rimary due to the accumulation of ammonia or secondary due
o multi-organ failure combined with hypotension, may develop in
esponse to abnormal liver and kidney functions (Barceloux, 2008).
mmonia, a by-product of protein metabolism, is neurotoxic at
igh concentrations (Ytrebo et al., 2006). The liver converts am-
onia to urea, which is excreted through the kidneys. Amatoxin-
ntoxicated patients with continued loss of hepatocellular function
re not able to transform ammonia to urea. Blood ammonia levels
ise and ammonia is delivered to the brain causing encephalopa-
hy, disorientation, confusion, lethargy, somnolence, vertigo, con-
ulsions, and coma (Bonnet and Basson, 2002).
.6.5. Treatment and management of intoxications by amatoxins
General treatment measures applied to amatoxins’ poisoned pa-
ients include: stabilization of vital functions, intensive and sup-
ortive measures, prevention of the poison absorption, exten-
ive hydration through i.v. route to protect kidneys and increase
he elimination of amatoxins, use of putative antidotes, enhanced
limination of the poison and prevention of complications (Diaz,
005b). Some of these measures have shown some degree of suc-
ess, while others show negligible efficacy (Table 3). At this point,
t can be said that a lot of research work still needs to be done to
chieve a satisfactory therapeutic efficacy against amatoxins intox-
cation.
.6.5.1. Dealing with intoxication cases. On a putative case of am-
toxins intoxication, the initial step is to take the clinical history
f the patient and perform stabilizing measures, if required. Fluid
nd electrolyte imbalance may occur in the gastrointestinal phase
r result from measures undertaken to eliminate the amatoxins.
ntravenous fluids may have to be given for extra-fluid and elec-
rolyte replacement with careful monitoring of clinical biochemical
evels (Faulstich, 1979). The effects of amatoxins on protein synthe-
is and the damage on liver cells will cause alteration on coagula-
ion factors (Faulstich, 1979), therefore optimal treatment includes
ntravenous vitamin K and fresh-frozen plasma (Alves et al., 2001).
iver damage should be assessed promptly as it allows determining
ow far is the damage caused and the best clinical actions to as-
ume. Laboratory evaluation should include liver and kidney func-
ion, testing aminotransferases, prothrombin time, blood urea ni-
rogen, creatinine, ammonia, fibrinogen, bilirubin, complete blood
ount, electrolyte analysis, amylase, lipase, and urinalysis (Diaz,
005a).
All the basic information, such as the amount, type (a sample of
he ingested mushroom is of outmost importance), time of mush-
ooms ingestion, the first evidence of symptoms, and the symp-
oms present at the moment of hospitalization are of great value
n the first contact with the possible amatoxins’ poisoned patient.
he time between ingestion and onset of symptoms is critical. Sud-
en onset of intense gastrointestinal symptoms after a delay of 6–
4 h, following a mushrooms meal, should raise the suspicion of
matoxin poisoning.
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Table 3
Summary of clinical therapy in amatoxins poisoning.




















Austria SLB 0.0 Hruby et al. (1983)
16 1980
–1981
Austria BPC + SLB 6.25 Hruby et al. (1983)




France BPC + SLB 2 17.8 Jaeger et al. (1993)




Germany BPC + SLB PL 4.8 Jander et al. (2000)
2 2000 Portugal BPC + SLB AC 0.0 Alves et al. (2001)
2 2000 Portugal BPC + SLB AC PL 2 0.0 Alves et al. (2001)
103 1971
–1995
Slovak Republic BPC HP, HD 7.8 Enjalbert et al.
(2002)












Slovak Republic SLB FD, HP, HD 0.0 Enjalbert et al.
(2002)




































NS SLB 4.0 Mengs et al. (2012)
126 1983
–1992
NS SLB + BPC 11.0 Mengs et al. (2012)
118 1957
–2005
NS SLB 5.1 Mengs et al. (2012)
249 1957
–2005
NS SLB + BPC 8.8 Mengs et al. (2012)
77 2008 Turkey BPC + SLB + NAC AC, GL HF 1 2.5 Ahishali et al.
(2012)
2 2009 Massachusetts BPC + SLB + NAC AC 0.0 Ward et al. (2013)
2 1999
–2012












Turkey BPC + NAC AC, GL HP 4.4 Akin et al. (2013)
16 2001
–2006
Turkey BPC AC, GL HP 18.7 Akin et al. (2013)
PS: plasmapheresis; HD: hemodialysis, HF: hemofiltration; HP: hemoperfusion, FD: forced diuresis; GL: gastric lavage; AC: activated charcoal; BPC: benzylpenicillin; SLB:
silybin; NAC: N-acetylcysteine; NS: not specified.






























































2.6.5.1.1. Identification of amatoxins and phallotoxins. If
A. phalloides-type mushrooms ingestion is plausible, gastric con-
tent, mushroom samples, and stool specimens, if available, should
be analyzed to verify the presence of amatoxins and phallotoxins
(Becker et al., 1976). Several methods can be used for identification
and quantification of amatoxins and phallotoxins in the specimens
of A. phalloides. Evaluation of these toxins in mushrooms has
been performed using reversed-phase high-performance liquid
chromatography (RP-HPLC) (Enjalbert et al., 1996, 2004, 1999,
1993, 1992; Garcia et al., 2015c; Hu et al., 2012), capillary elec-
trophoresis coupled to mass spectrometry (MS) (Rittgen et al.,
2008), liquid chromatography (LC) coupled to MS or to tandem
MS (Chung et al., 2007; Garcia et al., 2015c; Jansson et al., 2012)
and LC electrospray ionization time-of-flight-MS (LC/ESI-TOF-MS)
(Ahmed et al., 2010). RP-HPLC is the most commonly used method,
although the LC-MS method seems to provide the most reliable
and sensitive results.
The Meixner test can also be used if a specimen of the in-
gested mushroom is available for analysis (Bleuter and Vergeer,
1980). The test is based on an acid-catalyzed (using concentrated
hydrochloric acid) reaction of amatoxins with the complex biopoly-
mer lignin to form a blue product. As described by Meixner, the
test is run by squeezing the juice from a piece of fresh mush-
room tissue onto a piece of newsprint, which contains lignin, al-
lowing the spot to dry, and then applying one drop of concen-
trated hydrochloric acid. Formation of a blue color indicates a pos-
itive test (Bleuter and Vergeer, 1980). Nevertheless, the efficacy of
this test is limited by false positive results. Mushrooms contain-
ing hydroxyl-substituted tryptamine compounds, such as psilocin
or serotonin may also produce a positive Meixner reaction (Beuhler
et al., 2004), and therefore a positive test result requires further
confirmation of the mushroom identity.
A rapid and sensitive method that can be performed in the pa-
tient bed side, or within minutes in the hospital structures, would
be of outmost value for a better clinical assessment but it is not
available presently. Urine analysis is a vital tool for amatoxin poi-
soning surveillance, contributing to the management of suspected
mushroom poisoning (Butera et al., 2004). If analysis is performed
within 36 h of ingestion, α-amanitin can be detected in urine. Af-
ter 36 h, the analysis is unreliable and a negative result cannot rule
out poisoning (Karlson-Stiber and Persson, 2003). There are differ-
ent methods for urine analysis: radioimmunoassay, Enzyme Linked
Immunosorbent Assay (ELISA) and HPLC (Barceloux, 2008).
2.6.5.1.2. Minimizing absorption and inactivation of amatoxins in
the gastrointestinal tract. After careful consideration of the risks
to the intoxicated patient, gastrointestinal (GI) decontamination
should be considered based upon the time elapsed from ingestion
to time of presentation at the hospital. Several methods of GI de-
contamination that can be used alone or in combination include
gastric lavage, whole bowel irrigation, administration of activated
charcoal, and endoscopic or surgical removal of the ingested poison
(Albertson et al., 2011; Garcia et al., 2015b). Whole bowel irrigation
has a very limited impact in the treatment of human poisoning,
and therefore should not be used routinely in the management of
the poisoned patient (Albertson et al., 2011; Santi et al., 2012; Sey-
mour and Henry, 2001). Gastric lavage is most useful if attempted
within 1 h after the ingestion of a potentially life threatening poi-
son (Vale, 1997), while it is contraindicated in patients with loss
of airway protective reflexes, such as in a patient with a depressed
state of consciousness, and in patients who are at risk of hemor-
rhage or gastrointestinal perforation, as well as in patients that un-
derwent recent surgery or have other medical conditions such as
coagulopathy (Vale et al., 2004). Clinical toxicology database of the
United Kingdom national poisons information service (TOXBASE)
recommends gastric lavage up to 1 h after A. phalloides ingestion
(TOXBASE, 2008).Activated charcoal efficacy decreases with increased time
lapsed after ingestion, while the greatest benefit can be observed
ithin 1 h after ingestion of the poison (Albertson et al., 2011). The
fficacy of activated charcoal was not yet proven in controlled clin-
cal settings towards amatoxins ingestion, but activated charcoal
20–40 g every 3–4 h) has been administered routinely because it
ay also interrupt the enterohepatic circulation of amatoxins and
otentially reduce their toxicity (Garcia et al., 2015b). The center
f anti-poisoning information (CIAV) in Portugal and TOXBASE rec-
mmend a dose of 50 g every 4 h (CIAV, 2014; TOXBASE, 2008). If
omiting is troublesome, the dose can be reduced to 12.5 g char-
oal hourly or 25 g every 2 h (TOXBASE, 2008). As most patients
each the hospital emergency hours after ingesting the mush-
ooms, these clinical measures have limited efficacy, although they
re undertaken to assure the best clinical treatment available in a
ife risk situation, even before confirmation of amatoxin poisoning
Garcia et al., 2015b).
2.6.5.1.3. Elimination of absorbed amatoxins. As stated, excretion
f amatoxins is mainly urinary; therefore diuresis would poten-
ially increase the renal clearance and could be a potential good
herapy for this intoxication. Forced diuresis is recommended, with
rine output of 100–200 ml/h for 4–5 days (Mas, 2005). This pro-
edure is also recommended by CIAV and national poisons center
f New Zealand, especially in the first 48 h after ingestion (CIAV,
014; Toxinz, 2013).
Amatoxins are only detected in the plasma at the early phase
f poisoning and only for a short period of time. For that rea-
on, removing amatoxins by extracorporal elimination, particu-
arly hemodialysis, hemoperfusion or plasmapheresis, was previ-
usly considered to have no impact on patient survival (Jaeger
t al., 1993; Koppel, 1993). Some studies present some evidence
emonstrating benefits of molecular adsorbent recirculating sys-
em (MARS) in management of A. phalloides poisonings (Lionte
t al., 2005; Shi et al., 2002). However, these findings have not
een adequately corroborated, since only very few case reports
ave been published and further evidence is needed. In a re-
ent study, the effectiveness and safety of combined extracor-
oreal techniques using the fractionated plasma separation and
dsorption system, FPSA, Prometheus® 4008H, Fresenius Medical
are, Germany, in poisoned patients with A. phalloides was stud-
ed (Bergis et al., 2012). This technique consists on the elimina-
ion of the protein-bound and water-soluble toxin. Prometheus®
eemed to be a promising treatment for A. phalloides poisoning by
reventing the need for liver transplantation. However, such treat-
ent was administered associated to other therapies (silybin and
-acetylcysteine). MARS and Prometheus® are based in the same
rinciple, the extracorporeal elimination of toxins. As amanitin is
apidly eliminated from plasma, these techniques may be useful
f patients are presented to the hospital when the first symptoms
ppear not after“ with ”are based in the same principle, the extra-
orporeal liver support, however more clinical studies are needed
o demonstrate its effectiveness.
.6.5.2. Drug therapy. Based on pre-clinical findings, several treat-
ents have been applied in intoxications by amatoxins, namely
ormones (insulin, growth hormone, glucagon), steroids, vitamin
, vitamin E, cimetidine, α-lipoic acid, antibiotics (benzylpenicillin,
eftazidime), N-acetylcysteine, and silybin (Enjalbert et al., 2002).
rom these, only benzylpenicillin, ceftazidime, N-acetylcysteine,
nd silybin were proven to have some degree of therapeutic effi-
acy, although the death rate remains extremely high (Poucheret
t al., 2010) (Table 3). Some of the most used procedures that
howed some clinical effectiveness are addressed below.
2.6.5.2.1. β-Lactam antibiotics. The most widely used drug in
he management of amatoxin poisoning, in monotherapy or in
ombination with other agents is benzylpenicillin. One study in-





























































































































olving 47 patients poisoned with A. phalloides demonstrated that
enzylpenicillin combined with supportive measures was an effec-
ive treatment in 43 cases (Table 3) (Moroni et al., 1976). The ef-
ectiveness of benzylpenicillin was, also, evaluated in a retrospec-
ive study including 111 patients treated from 1988 to 2002 in the
oxicological Unit of Careggi General Hospital for amatoxin poi-
oning (Giannini et al., 2007). The administration of benzylpeni-
illin combined with intensive fluid and supportive therapy, resti-
ution of the altered coagulation factors, multiple-dose activated
harcoal, mannitol, dexamethasone and reduced glutathione (GSH)
esulted in the complete recovery of all patients treated within
6 h after mushroom ingestion (Table 3) (Giannini et al., 2007).
owever, two patients admitted to the hospital more than 60 h
fter mushroom ingestion died (Table 3) (Giannini et al., 2007).
n the other hand, benzylpenicillin monotherapy administered to
03 intoxicated patients resulted in an overall mortality of 7.8%
Table 3). Higher overall mortality (22.2%) was observed in Croa-
ia in a study that included 18 patients treated in 1988 (Table 3)
Enjalbert et al., 2002). Taken together, these results evidence that
enzylpenicillin has some therapeutic effectiveness, although the
igh mortality rate indicates that this antidote is far from ideal
Table 3).
In vitro studies using human hepatocytes provided some ev-
dence to support the effectiveness of benzylpenicillin in limit-
ng the cytotoxicity of amatoxins (Magdalan et al., 2010a, 2009).
n vivo studies, dogs (beagles, weighing 8–15 kg) were given an
ral dose of lyophilized A. phalloides, which contained 0.14 mg/g of
cid phallotoxins, 0.04 mg/g of acid amatoxins, 0.04 mg/g of neu-
ral phallotoxins, and 1.1 mg/g of neutral amatoxins. Benzylpeni-
illin (1000 mg/kg) was intravenously given at 5 h after poison-
ng and silymarin (50 mg/kg) was intravenously given at 5 h fol-
owed by a dose of 30 mg/kg at 24 h after poisoning. The results
howed that benzylpenicillin combined with silymarin helped pre-
ent liver damage, since the increases observed on blood amino-
ransferases (ALT and AST) and also alkaline phosphatase levels
nduced by A. phalloides were inhibited (Floersheim et al., 1978).
owever, the effectiveness of benzylpenicillin (intraperitoneal dose
f 1 million units/kg/day administered at 4 h after poisoning) may
e species dependent, as it was not found to be effective in lim-
ting hepatic injury in mice (weighed an average of 42.4 g) in-
uced by a single intraperitoneal dose of α-amanitin (0.6 mg/kg)
Tong et al., 2007). Dogs seem to be the model that closest re-
embles humans concerning intoxications by amatoxins, since the
linical course and symptoms are almost identical (Faulstich et al.,
985). Moreover, dogs and humans share a great oral bioavailabil-
ty for amatoxins (Faulstich et al., 1985). Despite the scarce oral
ioavailability in rodents, the toxic effects of amatoxins are sim-
lar to those found in humans (Kaya et al., 2014). Most studies
ith mice use intraperitoneal administration that could intensify
he amatoxins-induced organ damage. In fact, that can explain the
ack of efficacy of the antidotes in mice injected with high doses of
matoxins.
Several hypotheses have been proposed to explain the mecha-
isms of benzylpenicillin in amatoxin poisoning. It was previously
hought that benzylpenicillin could displace α-amanitin from al-
umin, allowing better renal elimination, but such hypothesis was
ater refuted by evidences demonstrating that α-amanitin does not
ind to serum albumin (Floersheim, 1983). The influence of ben-
ylpenicillin on the hepatic uptake of amatoxins has also been
tudied but remains unclear. Kroncke et al. studied amatoxins hep-
tic transport in membrane vesicles from rat liver using radio-
abeled α- and γ -amanitins (Kroncke et al., 1986). It was ob-
erved that amatoxin membrane transport was not inhibited by
enzylpenicillin. However, recent in vitro findings, using human
epatocytes, suggest that benzylpenicillin blocks α-amanitin up-
ake, being a potent inhibitor of OATP1B3 transporter (Letschertt al., 2006). Such putative protective effect requires further ex-
erimental in vivo confirmation.
Despite the reported efficacy of benzylpenicillin, this antidote
as safety issues. The administration of benzylpenicillin may re-
ult in high sodium salt concentration in the body, which can dis-
upt electrolyte balance. In addition, it may cause allergic reactions,
ranulocytopenia, and evoke neurotoxic symptoms in patients with
ervous system disease and renal insufficiency (Enjalbert et al.,
002).
Another β-lactam antibiotic used in the management of A. phal-
oides poisoning is ceftazidime. However, the number of amatoxin
oisoning cases treated with ceftazidime is limited (Poucheret
t al., 2010) and this antidote was always administered in com-
ination with silybin (Enjalbert et al., 2002), which causes bias to
ts putative protective effect. Further investigations are needed to
etter understand the underlying protective mechanism of action
f ceftazidime.
The Portuguese poisoning information center recommends a
ose of benzylpenicillin of 1 million units/kg/day, by continu-
us intravenous infusion (CIAV, 2014) in amatoxin poisoning. This
reatment should be maintained until clinical and laboratory im-
rovement is achieved, as observed by serum transaminases levels
nd prothrombin time. TOXBASE recommends a dose of 0.5 mil-
ion units/kg/day as a continuous infusion for 2–3 days after the
ay of ingestion, with close monitoring of renal function (TOXBASE,
008). However, the national poisons center of New Zealand does
ot recommend the use of benzylpenicillin (Toxinz, 2013) due to
ts safety issues and allergenic potential.
2.6.5.2.2. Silymarin. Silybum marianum (‘milk thistle’) is cur-
ently the most widely researched plant used in the treatment of
iver diseases. The active constituents of milk thistle are flavono-
ignans including silybin, silydianin, and silychristine, collectively
nown as silymarin. Silybin is the component with the highest an-
ioxidant activity, and ‘milk thistle’ extracts are usually standard-
zed to contain 70–80% silybin (Luper, 1998). Due to its antioxidant
ctivity, silybin has been applied in the management of amatoxin
oisoning and evidence on the effectiveness of silybin in poisoned
atients has been reported. Forty-six cases of amatoxin poisoning
reated with silybin as monotherapy showed that all patients sur-
ived (Table 3) (Enjalbert et al., 2002). These results indicate that
ilybin has some effectiveness in the management of amatoxin poi-
oning, exhibiting low mortality rates (Table 3). Silybin seems to
e more effective as monotherapy than when combined with ben-
ylpenicillin. In fact, in a recent study based on 1500 documented
ases, it was concluded that the overall mortality in intoxicated
atients with A. phalloides treated with silybin, as Legalon® SIL
silibinin-C-2′,3-dihydrogen succinate, disodium salt), is less than
0% in comparison to more than 20% when using benzylpenicillin
r a combination of silybin and benzylpenicillin (Mengs et al.,
012).
Cytotoxicity evaluation on cultured human hepatocyte using
TT reduction and leakage assays was performed after 12, 24 and
8 h exposure to α-amanitin (2 μM) and/or silybin. The treatment
ith silybin showed a strong protective effect against cell damage
n α-amanitin-induced toxicity (Magdalan et al., 2010a).
The protective effects of silymarin on amatoxin poisoning have
lso been studied in different animal models. Again, species differ-
nces were found, since a significant hepatoprotective effect was
bserved for silybin in α-amanitin-induced liver damage in dogs
Vogel et al., 1984), while no protective effect was observed in
ice (Tong et al., 2007). In both species, the α-amanitin LD50 was
dministered; however different administration routes were used.
-Amanitin was administered orally to dogs while in mice it was
dministered intraperitoneally. It is reasonable to consider that α-
manitin-induced toxicity in mice could be enhanced by intraperi-
oneal administration and, in that case, the overall protection

































































induced by silybin failed. Moreover, inter species differences may
also exist.
As mentioned above, the postulated protective mechanisms of
action mediated by silybin are associated to its strong antioxidant
activity, which could explain its action against hepatotoxic agents
that act through oxidative stress. Silybin and silymarin reduce the
free radical load, stimulate the activity of SOD and increase GSH
levels (Fraschini et al., 2002). Moreover, Pradhan and Girish (2006)
suggest that silymarin is able to enter the nucleus and specifically
stimulate RNA polymerase I activity. This effect increases the tran-
scription of ribosomal RNA, which may counterbalance the inhibi-
tion of RNAP II induced by amatoxins (Pradhan and Girish, 2006).
Nevertheless, this hypothesis needs further confirmation. Another
important effect of silybin is the inhibition of the organic anion-
transporting polypeptides (OATPs) (Wlcek et al., 2013), which may
prove to be crutial to prevent the uptake of amanitin by hepato-
cytes.
Based on animal studies and limited human data, it seems
that silybin has been the most promising molecule to prevent
pathophysiological events after amatoxin intoxications, with a good
safety profile. Therefore, CIAV and the national poisons center of
New Zealand recommend an intravenous administration of 20–
50 mg/kg/day in four divided doses. Treatment should be contin-
ued for 48–96 h after mushroom ingestion (CIAV, 2014; Toxinz,
2013). TOXBASE recommendations for A. phalloides poisoning treat-
ment do not include silybin administration (TOXBASE, 2008) prob-
ably due to the low clinical evidence available so far concerning
silybin efficacy.
2.6.5.2.3. N-acetylcysteine. N-acetylcysteine has been in medi-
cal use for more than 50 years as a mucolytic agent. It is also
a well-known treatment for acetaminophen overdose, and related
liver damage (James et al., 2003). Due to the clinical similarity
between acetaminophen overdose and amatoxin poisoning, both
leading to hepatic and renal necrosis, N-acetylcysteine has been
applied in the management of amatoxins poisoning. This com-
pound is a precursor of GSH and due to its antioxidant and
liver protecting effects it is postulated to play a protective role
in patients poisoned with A. phalloides. N-acetylcysteine, adminis-
tered to 86 amatoxins poisoned patients showed overall survival
of 93.0% (Table 3) (Enjalbert et al., 2002). A retrospective multi-
dimensional multivariate statistical analysis of 2110 clinical cases
of amatoxin poisoning was performed in order to optimize ther-
apeutic decision-making (Poucheret et al., 2010). The results of
this study showed that N-acetylcysteine has a statistically posi-
tive impact on amatoxin poisoning (Poucheret et al., 2010). A ret-
rospective study including 40 amatoxins-intoxicated patients was
performed in order to investigate the benefits of N-acetylcysteine
treatment in addition to the standard treatment that included ben-
zylpenicillin in patients with A. phalloides intoxication (Akin et al.,
2013). The mortality rate was lower when N-acetylcysteine was co-
administered (4.4% vs 18.7% in the group that received only ben-
zylpenicillin). Thus, the authors concluded that A. phalloides intox-
ication could be successfully treated with N-acetylcysteine in addi-
tion with benzylpenicillin (Akin et al., 2013). N-acetylcysteine can
act at two levels: by direct ROS scavenging and/or restoring hep-
atic GSH (Poucheret et al., 2010). In accordance, a recent in vitro
study showed that treatment of human hepatocyte cultures with
N-acetylcysteine gave a strong protective effect against subsequent
α-amanitin cytotoxicity (Magdalan et al., 2010a).
On the other hand, research previously conducted by Schnei-
der et al. and Tong et al. failed to show any relevant clinical effi-
cacy of N-acetylcysteine in the treatment of A. phalloides intoxica-
tion in mice (Schneider et al., 1992; Tong et al., 2007). Both studies
used 1.2 g/kg of N-acetylcysteine administered 4 h after intraperi-
toneal administration of α-amanitin (0.6 mg/kg). Efficacy data of
N-acetylcysteine administration in α-amanitin-intoxicated dogs areacking. However, it is reasonable to consider that there is no rea-
on to not include N-acetylcysteine in the treatment regimen.
CIAV and TOXBASE protocols for A. phalloides poisoning do not
nclude administration of N-acetylcysteine (CIAV, 2014; TOXBASE,
008), whereas the national poisons center of New Zealand recom-
ends to administer 150 mg/kg in 200 mL vehicle (5% dextrose in
ater) intravenously over 15 min followed by 50 mg/kg in 500 mL
ehicle over 4 h followed by 100 mg/kg in 1000 mL vehicle over
6 h (Toxinz, 2013).
.6.5.3. Liver transplantation. In some cases of A. phalloides poison-
ng, acute liver failure can be developed and a consequent liver
ransplant is needed to guarantee patients’ survival. Acute liver
ailure has a devastating effect characterized by sudden and severe
iver cell dysfunction. This catastrophic illness can rapidly progress
o coma and death due to cerebral edema and multi-organ sys-
em failure (Larson, 2008). Several criteria to decide the timing
f liver transplantation have been proposed, although they are
ot universally accepted. The most widely used criteria for liver
ransplantation were developed by The Liver Unit at King’s Col-
ege Hospital (O’Grady et al., 1989). Their prognostic model was
ased on prothrombin time, age, etiology, time passing between
ppearance of jaundice and onset of encephalopathy, and biliru-
in concentration. These criteria differentiate acetaminophen and
on-acetaminophen induced acute liver failure. The King’s College
ospital prognostic criteria for non-paracetamol-induced fulminant
epatic failure includes: prothrombin time >100 s; and any three
f the following: age <10 or >40 years; jaundice >7 days before
nset of encephalopathy, prothrombin time >50 s and bilirubin
300 μmol/l (O’Grady et al., 1989). However, the application of
ing’s college criteria for non-acetaminophen induced acute hep-
tic failure on A. phalloides poisoning is limited (O’Grady et al.,
989). Not all variables included in these criteria are useful in pre-
icting a fatal outcome. In a distinct rationale, liver transplantation
ased on the Clichy criteria include the combination of decrease in
actor V below 30% of normal patients over 30 years or below 20%
f normal patients below 30 years and grade 3–4 encephalopa-
hy (Bernuau, 1993). On the other hand, a retrospective study of
98 amatoxins intoxicated patients showed that prothrombin index
25% in combination with serum creatinine >106 μmol/L from
ay 3–10 after A. phalloides ingestion is a strong predictor of fa-
al outcome (Ganzert et al., 2005). Ganzert’s criteria do not in-
lude the evaluation of hepatic encephalopathy due to imprecise
ata in the patients’ records (Ganzert et al., 2005). In order to re-
ssess the transplantation criteria, Escudie et al. studied 27 A. phal-
oides poisoned patients and the above criteria were compared. En-
ephalopathy, an absolute prerequisite in Clichy criteria for decid-
ng emergency transplantation, was not fully observed in this study
Escudie et al., 2007). Not all patients with a fatal outcome devel-
ped encephalopathy and, in those who developed, the mean in-
erval between the onset of encephalopathy and death was very
hort (Escudie et al., 2007). Comparing to the Ganzert’s criteria,
he prothrombin index below or equal to 25% of normal values,
etween day 3 and day 10 after amatoxins ingestion, was refuted
y Escudie et al. (2007). Their findings showed that 52% of pa-
ients that had a decrease in prothrombin index recovered with-
ut the need of transplantation. The authors concluded that such
rothrombin index should be lowered in order to avoid unneces-
ary transplantation (Escudie et al., 2007). Moreover, it was also
hown that the value of serum creatinine has some limitations.
scudie et al. (2007) found that not all patients with fatal out-
ome had a creatinine level over 106 μmol/L 3 days or more af-
er ingestion. The authors suggested that serum creatinine should
ot be an absolute requirement for emergency transplantation.
hey also pointed out that liver transplantation should be strongly
ecommended in patients with an interval between ingestion of

























































































ushrooms and the onset diarrhea lower than 8 h (Escudie et al.,
007). In addition to this interval, females were also more at risk
or a fatal outcome than males. Lastly, decrease in prothrombin in-
ex below 10% of normal (international normalized ratio > 6) 4
ays or more after ingestion should be a strong plus to consider
n emergency transplantation (Escudie et al., 2007).
A recent publication has shown that polymyxin B has partially
revented the amanitin-induced toxicity when a lethal dose of α-
manitin was used in CD-1 mice. As polymyxin B showed in silico
nd in vivo to avoid RNA polymerase II inactivation (Garcia et al.,
015d), this recent finding further support the new paradigm of
ntidotal route for Amanita phalloides poisoning focusing on RNA
olymerase II.
. Conclusions
A. phalloides is one of the most toxic mushrooms and is in-
olved in the majority of human fatal cases of mushroom poison-
ng. The true incidence of amatoxin poisoning is unknown due to
ub notification cases of intoxication cases, and therefore mortal-
ty rates reported in the literature may be significantly underesti-
ated.
When A. phalloides poisoning occurs, most patients are admit-
ed to hospital at a late stage, and often no appropriate tools for
nalyzing amatoxins or corroborate the poisoning are available.
he presumed diagnosis of amatoxin poisoning is often suggested
ased on a gastrointestinal syndrome preceded by a latent period
nd a history of mushrooms ingestion. Treatment often aims de-
ontamination, control of fluid and electrolyte balance and preven-
ion of multiple organ failure, especially liver failure.
The optimal management of the A. phalloides poisoning remains
o be determined, which makes difficult the establishment of a
orldwide standard treatment. In fact, this can explain the ther-
peutic differences between the different poisons centers analyzed
hroughout the globe. Some options have been employed and in-
lude detoxification measures, chemotherapy, and liver transplan-
ation as the last resort. Retrospective analysis of the applied ther-
py, specifically using benzylpenicillin, ceftazidime, silybin, and N-
cetylcysteine, has revealed contradictory results regarding to their
linical effectiveness. The lack of randomized, controlled clinical
rials in combination with the use of combined therapy and the
verall underreported intoxication cases limit the true evaluation
f the efficacy of a specific therapy. Silybin seems a promising
rug to prevent amatoxins-induced intoxications symptomatology
emonstrating a good safety profile and so far it has presented the
owest mortality rate of the applied treatments. Despite the mor-
ality rate being below 10%, the patients’ prognosis largely depends
n the prompt recognition and treatment. Even so, more clinical
tudies and in vivo experimental data are needed to prove its use
n the clinical practice.
Emergency liver transplantation is the only intervention with
ecognized survival benefits in acute liver failure patients with
poor prognosis. Nevertheless, liver failure may develop rapidly
ithin days, hindering timely hepatic transplant.
Inhibition of the RNAP II has been postulated to be the main
oxic mechanism of α-amanitin. Other mechanisms have been
ointed but need further investigation. A more detailed under-
tanding of the above mechanism will aid in the development of
ffective and more powerful drugs for treating amatoxins poison-
ng. An important approach would be to develop an antidote that
ompetes with amatoxins and displaces them from RNAP II. In fact,
n optimal agent should be able to bind to RNAP II protecting
gainst amatoxins while not disturbing the normal transcription
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